Angptl3 Activators

The class of ANGPTL3 activators primarily comprises compounds that modulate lipid metabolism through various mechanisms. These activators include fibrates like Fenofibrate and Gemfibrozil, which are PPARα agonists, and glitazones like Rosiglitazone and Pioglitazone, which are PPARγ agonists. These drugs, by activating their respective peroxisome proliferator-activated receptors, indirectly increase the expression of ANGPTL3, influencing lipid processing and metabolism. Fibrates are particularly effective in reducing triglyceride levels and increasing HDL cholesterol, while glitazones primarily impact glucose metabolism and insulin sensitivity.

Additionally, this class includes LXR agonists such as GW3965 and T0901317, which regulate cholesterol homeostasis and lipid metabolism, thus affecting ANGPTL3 expression. LXR agonists are known for their role in cholesterol efflux and reverse cholesterol transport. On the other hand, LXR antagonists like GSK2033 offer an alternate pathway to modulate ANGPTL3 activity, suggesting a complex regulatory network. The inclusion of statins such as Atorvastatin, Simvastatin, and Lovastatin in this category represents their indirect influence on ANGPTL3 expression. While their primary action is the inhibition of HMG-CoA reductase, leading to decreased cholesterol synthesis, their impact on lipid metabolism pathways can extend to modulating ANGPTL3 levels.